Vectura Group (VEC) Share Price, News & Analysis

Company Overview

Vectura Group plc engages in the design, development, and supply of pharmaceutical products for the treatment of airways-related diseases worldwide. The company's in-market products include Seebri, Breezhaler and Neohaler, a DPI device and bronchodilator; AirFluSal Forspiro for the treatment of asthma and chronic obstructive pulmonary disease (COPD); Breelib for the treatment of pulmonary arterial hypertension; Relvar Ellipta/Breo Ellipta that is used in treating asthma and COPD; and Incruse Ellipta, Anoro Ellipta, and Trelegy Ellipta for the treatment of COPD. It is also developing VR315 (US) for the treatment of asthma and COPD.In addition, the company offers dry powder inhalers, pressurized metered dose inhalers, and nebulized devices. Vectura Group plc was founded in 1997 and is headquartered in Chippenham, the United Kingdom.

Key Stats

• Today's Range: N/A
• 50-Day Range: 164.80 to 164.80
• 52-Week Range: N/A
• Volume: 203,761 shs
• Average Volume: 3.37 million shs
• Market Capitalization: £1.01 billion
• P/E Ratio: 8.20
• Dividend Yield: 23.06%
• Price Target: N/A
• Consensus Rating: N/A

VEC Stock Analysis - Frequently Asked Questions

How do I buy shares of Vectura Group?

Shares of VEC stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What other stocks do shareholders of Vectura Group own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Vectura Group investors own include Hikma Pharmaceuticals (HIK), SEB (SKP), BTG (BTG), iRobot (IRBT), Sinclair Pharma (SPH), Sirius Minerals (SXX) and Coats Group (COA).

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Medical
• Industry: Drug Manufacturers - Major
• Sub-Industry: N/A
• Current Symbol: LON:VEC
• CUSIP: N/A
• CIK: N/A
• Web: www.vectura.com
• Phone: +44-1249-667700
• Fax: N/A
• Employees: 9,200
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: 8.20
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 0.77
• Current Ratio: 3.59
• Quick Ratio: 3.20

Sales & Book Value

• Annual Sales: £190.60 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: 12.48
• Book Value: GBX 91.70 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 613,892,000
• Free Float: N/A
• Market Cap: £1.01 billion
• Optionable: Not Optionable
• Beta: N/A